Aurobindo Pharma Limited has announced the termination of its License Agreement with Hilleman Laboratories Singapore Pte. Limited through its wholly owned step-down subsidiary, Auro Vaccines Private Limited. The agreement, originally signed on September 27, 2023, was aimed at the development, manufacturing, and commercialization of a pentavalent vaccine candidate used in children’s vaccination.
Key details of the termination:
- Termination date: March 5, 2025
- Reason: The vaccine asset was in its early-stage development, and its termination is not considered a material event.
- Impact on Aurobindo Pharma: The company has stated that this termination will not have a significant impact on its operations, subsidiaries, or financials. Any future impact will be disclosed as required.
The company has assured that despite this decision, its overall business strategy remains strong, and it will continue to explore new opportunities in the vaccine development segment.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
